Home | Mission | Join Us ! | Bylaws | Sponsors | Contact Us
 
  Executive Committee
  Members
  Committees
  Venous Registries
  Meetings
  Useful Venous Links
 
 

Master Class & workshop
on Chronic Venous Disease

August 14 -15, 2009
Manipal Hospital Bangalore, India


Join Us in January!
VAI MEETINGS

VAICON 2010
Bengaluru (Bangalore), India


VAICON 2011
Rajkot, India

VAICON 2012
Kochi (Cochin), India


VAICON 2013
Chandigarh, India

 
 
Weekly Venous News
 
The clinical significance of below-knee great saphenous vein reflux following endovenous laser ablation of above-knee great saphenous vein.

Theivacumar NS, Darwood RJ, Dellegrammaticas D, Mavor AI, Gough MJ. Leeds Vascular Institute, The General Infirmary at Leeds, Great George Street, Leeds LS1 3EX, UK.

AIMS: The standard technique for endovenous laser ablation (EVLA) for varicose veins due to great saphenous vein (GSV) reflux involves obliteration of the above-knee (AK) GSV. This study assesses the significance of persistent below-knee (BK) GSV reflux following such therapy.

METHODS: Sixty-nine limbs (64 patients) with varicosities and GSV reflux underwent AK-EVLA. Post treatment, GSV reflux (ultrasound: six, 12 weeks) and Aberdeen varicose vein severity scores (AVVSS, 12 weeks) were assessed, and residual varicosities treated with foam sclerotherapy (six weeks).

RESULTS: The untreated BK-GSV remained patent in all limbs. Ultrasound showed normal antegrade flow in 34/69 (49%, Group A), flash reflux <1 s in 7/69 (10%, Group B) and >1 s reflux in 28/69 (41%, Group C). Although AVVSS improved in all groups (P < 0.001): A: 14.6 (8.4-19.3) versus 2.8 (0.5-4.4), B: 13.9 (7.5-20.1) versus 3.7 (2.1-6.8), C: 15.1 (8.9-22.5) versus 8.1 (5.3-12.6) the improvement was less in Group C (P < 0.001 versus A and B) and was associated with a greater requirement (A: 4/34 [12%]; B: 1/7 [14%]; C: 25/28 [89%]) for sclerotherapy (persisting varicosities) (P < 0.001).

CONCLUSION: Although AK-GSV EVLA improves symptoms regardless of persisting BK reflux, the latter appears responsible for residual symptoms and a greater need for sclerotherapy for residual varicosities.

Phlebology, 2009;24(1):17-20.